GSK to Acquire 35Pharma

Paul, Weiss is advising GSK plc in its $950 million all-cash acquisition of 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company specializing in the development of novel protein-based therapeutics. The deal includes the acquisition of HS235, a potential best-in-class investigational medicine for the treatment of pulmonary hypertension and pulmonary arterial hypertension.

The Paul, Weiss team is led by corporate partners Krishna Veeraraghavan and Benjamin Goodchild; intellectual property partners Jonathan Ashtor, Meggin Bednarczyk and Marisa Geiger, and counsel Matthew Rosenberg; antitrust partner Christopher Wilson; executive compensation partner Jean McLoughlin; tax partner Brian Krause; and litigation counsel Audrey Paquet.